摘要
目的 探讨代谢综合征（MS）与前列腺癌（PCa）患者发生去势抵抗和骨转移的相关性.方法 回顾性分析2011年1月至2015年6月山西医科大学第一医院泌尿外科接受持续性内分泌治疗的104例PCa患者的资料,分为MS组和非MS组,结合前列腺磁共振成像（MRI）、骨扫描、前列腺特异抗原（PSA）、睾酮等指标,随访观察18个月.采用t检验比较两组患者到达去势抵抗期和骨转移的发生情况.结果 MS组35例,非MS组69例,两组的年龄、PSA、Gleason评分、分期、吸烟情况比较,差异均无统计学意义（均P〉0.05）;体质量指数（BMI）、空腹血糖、血压、血脂等方面比较,差异均有统计学意义（均P〈0.05）.随访期间,MS组进展为去势抵抗性PCa（CRPC）16例,非MS组进展为CRPC 18例,两组比较差异有统计学意义（χ2=4.065,P=0.044）;MS组发生骨转移11例,非MS组发生骨转移11例,两组比较差异有统计学意义（χ2=4.409,P=0.036）.MS组未进展为CRPC患者的生存率与非MS组相比,差异有统计学意义（χ2=7.034,P=0.021）;MS组无骨转移患者的生存率与非MS组相比,差异有统计学意义（χ2=6.082,P=0.029）.结论 MS促进PCa发生去势抵抗和骨转移,是PCa进展过程中的高危因素.对合并MS的PCa患者要高度重视,规范诊治MS相关疾病可能更好地控制PCa.
Objective To investigate the association between metabolic syndrome （MS） and castrate resistance, bone metastasis in patients with prostate cancer （PCa）. Methods A total of 104 patients with PCa who underwent persistent endocrine therapy in urology department of the First Hospital of Shanxi Medical University from January 2011 to June 2015 were analyzed retrospectively. They were divided into MS and non-MS group. Combined with magnetic resonance imaging （MRI）, bone scanning, prostate-specific antigen （PSA） and testosterone, the patients were followed-up for 18 months. The t test was used to compare the two groups of patients reached the castration resistance period and the occurrence of bone metastases. Results There were 35 patients in MS and 69 patients in non-MS group. There was no significant difference in age, PSA, Gleason score, staging, smoking between MS group and non-MS group （all P〉 0.05）; there were significant differences in body mass index （BMI）, fasting blood glucose, blood pressure and blood lipid between MS group and non-MS group （all P〈0.05）. 16 patients in MS group progressed to castration resistant prostate cancer （CRPC） and 18 patients in non-MS group progressed to CRPC, the difference was statistically significant （χ2= 4.065, P= 0.044）. MS group had 11 cases of bone metastasis and non-MS group had 11 cases of bone metastasis, and the difference was statistically significant （χ2= 4.409, P= 0.036）. The survival rate of patients without CRPC in MS group and non-MS group had a significant difference （χ2=7.034, P=0.021）. The survival rate of patients without bone metastasis in MS group and non-MS group also had a significant difference （χ2= 6.082, P= 0.029）. Conclusions MS can promote the occurrence of CRPC and bone metastasis in PCa, which is a high risk factor in the progression of the disease. PCa patients with MS should pay attention to the diagnosis and treatment of MS related diseases, which will be better for controlling PCa.
出处
《肿瘤研究与临床》
CAS
2018年第1期43-46,56,共5页
Cancer Research and Clinic
基金
山西省科技攻关项目（社会发展类）（20140313011-12）
山西省回国留学人员科研资助项目（2015-099）
关键词
前列腺肿瘤
代谢综合征
内分泌治疗
去势抵抗性
骨转移
Prostate neoplasms
Metabolic syndrome
Endocrine therapy
Castration resistance
Bone metastasis
